← Back

Wire · operational-macro

FDA Approves INOVIO's First DNA Immunotherapy for Rare Disease

Published

1 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at mychesco.com →

◆ Verified

Fusion42 · 3 November 2026 · Fusion42 review

The FDA has granted accelerated approval for INOVIO's VOCERYQ, the first plasmid DNA-based immunotherapy in the U.S., to reduce repeated surgeries in adults with recurrent respiratory papillomatosis. The approval marks a milestone for DNA medicine and requires a confirmatory clinical study by mid-2027.

This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 1 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

Biotech founders focusing on DNA therapies can now enter the US market with faster approval routes. Getting a firm clinical plan in place quickly will be critical as confirmatory trials are mandatory for ongoing approval.

◆ Coverage

9 sources · first reported 1 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaldna-immunotherapyrare-diseaseaccelerated-approvalinovio